*	OR T1 T2
R1	Has_value Arg1:T3 Arg2:T4	
R2	Has_temporal Arg1:T6 Arg2:T7	
R3	Has_mood Arg1:T6 Arg2:T5	
R4	Has_value Arg1:T10 Arg2:T11	
R5	AND Arg1:T12 Arg2:T10	
R6	Has_qualifier Arg1:T13 Arg2:T14	
R7	Subsumes Arg1:T13 Arg2:T15	
R8	Has_value Arg1:T15 Arg2:T16	
R9	Has_value Arg1:T18 Arg2:T19	
R10	Has_value Arg1:T20 Arg2:T21	
*	OR T24 T25
*	OR T27 T28
R11	AND Arg1:T26 Arg2:T27	
R12	multi Arg1:T30 Arg2:T31	
R13	Has_temporal Arg1:T30 Arg2:T9	
*	OR T32 T33 T30
R14	Has_temporal Arg1:T32 Arg2:T9	
R15	Has_temporal Arg1:T33 Arg2:T9	
*	OR T8 T34
T1	Condition 0 9	Pregnancy
T2	Observation 14 28	breast feeding
T3	Observation 38 63	Estimated life expectancy
T4	Value 64 74	<12 months
T5	Mood 77 86	Scheduled
T6	Procedure 87 100	major surgery
T7	Temporal 101 121	in the next 6 months
T10	Measurement 424 427	WHO
T11	Value 428 448	group II, III, IV, V
T12	Condition 449 451	PH
T13	Condition 460 477	Renal dysfunction
T14	Qualifier 453 459	Severe
T15	Measurement 479 482	Ccr
T16	Value 482 492	<30 ml/min
T18	Measurement 495 515	Blood platelet count
T19	Value 515 525	<100,000/L
T20	Observation 527 545	Expected life span
T21	Value 545 553	<6-month
T22	Condition 555 580	Systematical inflammation
T23	Condition 582 598	Malignant cancer
T24	Condition 603 627	Tricuspid valve stenosis
T25	Condition 629 659	Supra-pulmonary valve stenosis
T26	Condition 661 669	Allergic
T27	Drug 673 686	studied drugs
T28	Drug 673 680;690 705	studied metal materials
T9	Temporal 288 296	Previous
T30	Procedure 324 362	treatment with an investigational drug
T31	Drug 342 362	investigational drug
T32	Observation 297 320	enrolment in this study
T33	Device 366 372	device
T8	Observation 124 156	Inability to follow the protocol
T34	Observation 124 136;161 195	Inability to comply with follow-up requirements
